COVID-19 Exacerbates Challenges For ATMP Developers In The EU
The Number Of Advanced Therapy Products On The Market Remains Low
Executive Summary
The COVID-19 pandemic has added to the many hurdles companies face when it comes to developing and marketing advanced therapy medicinal products in the EU. Jackie Mulryne of law firm Arnold & Porter suggests some factors they should consider when planning their EU market strategy for ATMPs.